Drugs / BIIB131
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05764122 | Mar 2024 → Jul 2025 | ischemic stroke | Biogen | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06990867 | May 2025 → Oct 2029 expected | ischemic stroke | Corxel Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05764122 ↗ |
| Known as | JX10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06990867 ↗ |
| Route | Intravenous | “continuous IV infusion” NCT05764122 ↗ |